Vir Biotechnology, Inc.

NASDAQ:VIR

Biotechnology

Healthcare
$9.15 -2.63%

-$0.25 today

Market cap
$1.57B
Beta
1.64
P/E (TTM)
-3.0
EPS (TTM)
-$3.00
52W Low $4.16High $11.66

Volume 2.15M

Average 1.76M

VIR Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Vir Biotechnology, Inc.NASDAQ: VIR

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense growth accelerates

Q1 FY2026 income tax expense of $170K rose 962.5% year over year, ahead of the +126.4% change in trailing-twelve-month income tax expense. Over 3 fiscal years it compounded at -90.3% a year.

Context

  • Income tax expense amounted to 0.3% of revenue in FY2025, down 1.2 pp from a year earlier.
  • Income tax expense increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +962.5% holds above the trailing-twelve-month pace of +126.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$170K+224.1% QoQ
Last fiscal yearDec 2025
$217K+119.0% YoY
LTMMar 2026
$371K+126.4% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+962.5%——
1 year+119.0%——
3-year CAGR-90.3%——
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
217K USD
Year-over-year change
+119.0%
4-year CAGR
-68.2%

Income Tax Expense vs competitors

How VIR compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +126.4% is the 3rd highest of 9, against a peer median of -40.9%.
  • Income tax expense amounts to 0.6% of revenue for VIR, versus a peer median of 0.3%.
VIR Competitors
Income Tax Expense for VIR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRNAModerna, Inc.LTM Sep 2026$60M USD+262.2%-64.6%2.4%
BNTXBioNTech SELTM Jun 2026€55.58M EUR+228.1%-71.4%2.1%
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$3.49M USD-0.9%+8.9%0.4%
NVAXNovavax, Inc.LTM Mar 2026$1.65M USD-83.2%-24.3%0.3%
VALNValneva SELTM Mar 2026€423K EUR-81.0%—0.3%
VIRVir Biotechnology, Inc.LTM Mar 2026$371K USD+126.4%-90.3%0.6%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$92K USD+103.7%—0.1%
ABUSArbutus Biopharma CorporationLTM Mar 2026$0 USD——0.0%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$0 USD-100.0%—0.0%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026-$6.32M USD-804.0%——
Peer median (excluding VIR) —-40.9%-44.4%0.3%

Competitors are the stored peer set for VIR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.1B1.62B86.18M74.21M68.56M
Cost of Revenue513.87M620.97M572.83M478.65M11.71M
Gross Profit581.54M994.83M(486.65M)(404.44M)56.85M
Gross Margin53.1%61.6%-564.7%-545.0%82.9%
Research & Development448.01M474.65M579.72M506.5M432.8M
Selling, General & Admin000092.07M
Operating Expenses160.79M161.76M197.66M182.73M524.87M
Depreciation & Amortization5.81M6.78M19.45M14.56M11.68M
EBITDA555.61M761.06M(641.64M)(508.91M)(426.09M)
EBITDA Margin50.7%47.1%-744.5%-685.8%-621.5%
Operating Income420.75M833.07M(684.31M)(587.17M)(468.02M)
Operating Margin38.4%51.6%-794.0%-791.3%-682.7%
Interest Income439K28.09M86.99M71.81M40.24M
Interest Expense00000
Other Income / Expenses129.05M(78.79M)56.11M64.06M30.25M
Income Before Tax549.8M754.28M(628.19M)(523.11M)(437.77M)
Pre-Tax Margin50.2%46.7%-728.9%-704.9%-638.6%
Income Tax Expense21.22M238.44M(13.08M)(1.15M)217K
Net Income528.58M515.84M(615.06M)(521.96M)(437.99M)
Net Margin48.3%31.9%-713.7%-703.4%-638.9%
EPS (Basic)4.073.89(4.59)(3.83)(3.16)
EPS (Diluted)3.963.83(4.59)(3.83)(3.16)
Weighted Avg Shares129.88M132.61M134.13M136.25M138.52M
Weighted Avg Shares (Diluted)133.44M134.81M134.13M136.25M138.52M

Vir Biotechnology, Inc.

NASDAQ:VIR

Intrinsic Alpha fair value

Locked

Current Price

$9.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.